Mersana Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $16,361 | $12,598 | $2,293 | $9,245 |
Gross Profit | 16,361 | 12,598 | -14,952 | 8,822 |
EBITDA | -12,814 | -11,667 | -22,882 | -17,881 |
EBIT | -13,214 | -12,069 | -23,285 | -18,304 |
Net Income | -14,117 | -11,501 | -24,268 | -19,306 |
Net Change In Cash | 16,361 | 12,598 | 2,293 | 9,245 |
Free Cash Flow | -19,251 | -8,577 | -21,855 | -32,788 |
Cash | 107,750 | 78,868 | 58,998 | 75,186 |
Basic Shares | 123,558 | 122,721 | 122,440 | 121,424 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $40,497 | $36,855 | $26,581 | $43 |
Gross Profit | 40,497 | -111,414 | 25,654 | -131,970 |
EBITDA | -63,272 | -166,080 | -199,957 | -167,938 |
EBIT | -64,900 | -167,597 | -200,884 | -168,793 |
Net Income | -69,192 | -171,670 | -207,540 | -169,205 |
Net Change In Cash | 40,497 | 36,855 | 26,581 | 43 |
Cost of Revenue | -76,990 | |||
Free Cash Flow | -82,472 | -171,050 | -51,560 | -140,636 |
Cash | 107,750 | 174,561 | 280,712 | 177,947 |
Basic Shares | 122,539 | 116,112 | 93,654 | 70,580 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.11 |
2024-09-30 | -$0.09 |
2024-06-30 | -$0.20 |
2024-03-31 | -$0.16 |
